Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Pure Extracts Dual Vertical Approach Incorporating Cannabis and Psychedelic Compounds Is Starting To Pay Off

Apr 5, 2021 • 7:39 AM EDT
7 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

During the last month, Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) has reported several significant developments and is an opportunity that we are closely following.

From forming strategic partnerships to purchasing cannabis biomass to launch a line of cannabis 2.0 products, Pure Extracts has been executing on a series of initiatives that leave us bullish on the near and long-term outlook.

Over the next quarter, we expect Pure Extracts to report additional milestones and are favorable on how the management team has been advancing the business. So far this year, the company has been nothing short of an execution story and find the risk-reward profile to be favorable at current levels.

Forms Strategic Joint Venture with Psyence Group

Last week, Pure Extracts reported to have signed a letter of intent to form a joint venture with Psyence Group Inc. (CSE: PSYG) to develop superior techniques to extract psilocybin from psychedelic mushrooms. The joint venture will also focus on the development of advanced formulations that contain psilocybin for the long-term treatment of psychological trauma and the mental health consequences that are associated with it.

We consider Psyence to be a strategic partner for Pure Extracts and are favorable on the expertise that it brings to the joint venture. Psyence is one of the world’s first psychedelic mushroom companies to operate a federally legal commercial cultivation and extraction facility in Southern Africa. The management team is comprised of doctors and scientists who are working to make breakthrough developments in palliative care, neurology, neuroscience, and drug development.

Pure Extracts brings additional strategic assets to the joint venture and has a strong Canadian network of psychedelic mushroom experts. From cultivation to research & development, the company works with Dr. Alexander MacGregor and his team at the Toronto Institute of Pharmaceutical Technology (TIPT) and we are favorable on this aspect of the platform.

Pure Extracts operates a state-of-the-art processing facility and it recently submitted an application to Health Canada for a Dealer’s License. We believe the granting of a Dealer’s License to be one of the most significant potential growth catalysts for Pure Extracts and we are favorable on how the story has advanced.

As it relates to the joint venture, the companies plan to maximize the use of their combined infrastructure and networks to accomplish near-term milestones. With Pure Extract’s leverage to Canada’s and Psyence’s network in South Africa, Lesotho and Jamaica, the joint venture has the necessary expertise to rapidly develop natural psychedelics and novel drug delivery systems.

Another attractive aspect of Psyence is related to the leadership team’s experience in structuring and conducting clinical trials. One of the company’s near term goals is to participate in a human clinical trial that is based in Canada. We believe the relationship with Pure Extracts could support Psyence’s goals and will monitor how the partnership advances from here.

The partnership with Pure Extracts is expected to facilitate the importation of Psyence’s standardized psychedelic mushrooms into Canada. The relationship provides Psyence with the opportunity to further optimize its extraction methods and produce products that are needed for safe clinical research. Through the joint venture, the companies want to be able to provide the highest quality and most innovative psilocybin products for Canada.

Psyence is highly committed to conducting clinical research for the development of transformational treatments for mental health disorders, with a particular focus on oncology palliative care. We are favorable on the quality of the partnership with Pure Extracts and consider this relationship to be an important aspect of the story.

Purchases Cannabis to Launch a Vape and Edible Product Line

A week before the Psyence relationship was announced, Pure Extracts reported to have purchased over 500 kilograms of high potency dry cannabis flower. The purchase comes ahead of planned launch of its Pure Pulls vapes and Pure Chews edible gummies. We are bullish on the growth prospects that are associated with the launch of these products and expect it to serve as a major revenue driver for the platform.

We believe that Pure Extracts will be able to capitalize on the increasing demand for cannabis 2.0 products in Canada and will monitor how the story advances from here. The management team highlighted the demand for these products in British Columbia, Alberta, Saskatchewan and Ontario, and expects the shipment to generate more than $1 million of revenue.

The launch of the product line comes at an important time for business and we expect Pure Extracts to record impressive growth in the current quarter. One of the reasons we are confident in the launch of the product line is related to the amount of infrastructure and distribution that is in place. We expect the products to generate significant traction in the markets they are launched in and will monitor how revenues ramp higher on a quarter-over-quarter basis.

Acquires State-of-the-Art Processing Technology

A few weeks ago, Pure Extracts reported to have ordered a state-of-the-art cosolvent injection system (CIS) from Vitalis Extraction Technology Inc. This will improve the capabilities that Pure Extracts has and will make it one of the first companies in the world to have the innovative system.

The CIS has been developed to enhance the Vitalis carbon dioxide (CO2) extraction systems to achieve dramatically faster throughput capacities while producing higher-quality cannabis extracts. The Vitalis CIS has been designed to achieve the optimal ethanol cosolvent flow rate ranges for both cannabis and hemp extracts while balancing extract quality with efficiency.

Pure Extracts and Vitalis have a long history of collaboration and we are favorable on the existing relationship between the businesses. The machinery will allow Pure Extracts to ramp-up production much faster than expected while still producing premium cannabis oil extracts and we will monitor how it supports revenue growth on a going forward basis.

An Execution Story that is Trading for a Discount

During the last quarter, the cannabis and the psychedelic sectors have come off its 2021 highs and the recent trend has been mixed. We believe that Pure Extracts represents a differentiated growth opportunity that has significant potential growth catalysts and will monitor how the story continues to advance.

At current levels, we believe that Pure Extracts has a compelling valuation and is an opportunity that we are excited about. The management team has been working tirelessly on the formation of strategic partnerships and are favorable on this aspect of the story. Going forward, we believe the business is well positioned to capitalize on burgeoning markets and will monitor how the management team is able to position the platform for success.

We consider Pure Extracts to be a differentiated opportunity and believe that our readers should be aware of it. If you are interested in learning more about Pure Extracts, please send an email to support@technical420.com with the subject “Pure Extracts” to be added to our distribution list.













This press release may include predictions, estimates or other information that might be considered forward-looking within the meaning of applicable securities laws, including statements related to the Company’s ability to support its continued growth and fund the business’ sales and financial goals for at least the remainder of fiscal 2021 with proceeds remaining from its recent offering. While these forward-looking statements represent the Company’s current judgments, they are subject to risks and uncertainties that could cause actual results to differ materially, including risks and uncertainties associated with market conditions. You are cautioned not to place undue reliance on these forward-looking statements, which reflect the opinions of the Company’s management only as of the date of this release. Please keep in mind that the Company is not obligating itself to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. When used herein, words such as: “potential,” “expect”, “look forward,” “believe,” “dedicated,” “building,” or variations of such words and similar expressions are intended to identify forward-looking statements.

Pursuant to an agreement between StoneBridge Partners LLC and Pure Extracts Technologies Corp. we have been hired for a period of 180 days beginning November 1, 2020 and ending May 1, 2021 to publicly disseminate information about (PULL) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (PULL) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own one hundred seventy six thousand eight hundred and twenty nine (176,829) shares of (PULL), which we purchased via private placement. We plan to sell the “ZERO” shares of (PULL) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (PULL) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.